Gujarat Themis Biosyn Ltd's Sachin Patel to buy up to 5.25 lakh shares (0.5% stake)

What Gujarat Themis Biosyn Ltd announced

On 1 July 2026, Gujarat Themis Biosyn Ltd filed a disclosure with the BSE under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing states that promoter Sachin D. Patel intends to acquire equity shares of the company from Pharmaceutical Business Group (India) Limited. The acquisition is characterised as an inter‑se transfer within the promoter group, and therefore does not trigger a mandatory open‑offer.

"The acquirer hereby declares that the acquisition price would not be higher by more than 25% of the price computed in point 6."

The transaction is scheduled to be completed between 8 July 2026 and 14 July 2026.

Details of the proposed share acquisition

The price of Rs 395.75 per share is within the 25 % ceiling over the 60‑day VWAP of Rs 376.60, satisfying the SEBI requirement that the acquisition price not exceed the market price by more than 25 %.

Shareholding impact

The filing includes a before‑and‑after snapshot of the shareholding pattern:

• Before the transaction
  • Sachin Patel: 24,97,200 shares (2.29 % of total capital)
  • Themis Medicare Limited (seller): 5,12,40,000 shares (47.02 %)
• After the transaction (assuming full acquisition)
  • Sachin Patel: 30,22,200 shares (2.77 % of total capital)
  • Themis Medicare Limited: 5,07,15,000 shares (46.54 %)

The net increase of 5,25,000 shares for Patel aligns with the maximum number of shares disclosed for acquisition. The overall share capital of the company remains unchanged; only the distribution among promoters shifts marginally.

Key facts at a glance

Why this matters for investors

The disclosure is a routine intra‑group reshuffling of equity that does not dilute existing shareholders, as no new shares are issued. The transaction merely transfers ownership from one promoter‑related entity to another, marginally increasing Patel’s voting power from 2.29 % to 2.77 %. Because the acquisition falls under the exemption clause of SEBI Regulation 10(1)(a)(ii), the company is not obliged to make a public offer to other shareholders, and the process is expected to be swift.

For investors, the key considerations are:

• Shareholding stability – The promoter group retains a dominant stake, and the overall promoter shareholding remains above 50 %.
• Regulatory compliance – All required declarations under the SAST regulations have been made, indicating that the transaction adheres to disclosure norms.
• Financial impact – The cash outlay of up to Rs 20 crore is an internal transfer; it does not affect the company’s balance sheet directly, nor does it alter earnings or cash flows.

Conclusion

Gujarat Themis Biosyn Ltd has formally notified the exchanges that promoter Sachin D. Patel will acquire up to 5.25 lakh shares (0.5 % of capital) from Pharmaceutical Business Group (India) Ltd at Rs 395.75 per share, valuing the deal at roughly Rs 20 crore. The acquisition is scheduled for 8‑14 July 2026 and qualifies for an exemption from a mandatory open‑offer. Post‑transaction, Patel’s shareholding will rise modestly, while the overall promoter control of the company remains unchanged. The filing satisfies all SEBI disclosure requirements, and no further regulatory approvals are pending for the transaction.

---

FAQs

1. What is the purpose of this acquisition? The filing states the rationale is an “inter‑se transfer among the promoter and promoter group,” indicating a reallocation of shares within the same controlling family.

2. Will existing shareholders be offered to buy shares? No. The transaction is exempt from a public open‑offer under SEBI Regulation 10(1)(a)(ii) because it involves an intra‑group transfer of less than 0.5 % of the share capital.

3. How does the price compare with the market price? The acquisition price of Rs 395.75 per share is within the 25 % ceiling over the 60‑day volume‑weighted average market price of Rs 376.60, complying with the SEBI pricing rule.

4. Will this dilute the equity of other shareholders? No new shares are being issued; the transaction merely moves existing shares from one promoter‑related entity to another, so there is no dilution.

5. What will be the promoter’s final holding percentage? Assuming the full acquisition of 5.25 lakh shares, Sachin Patel’s holding will increase from 2.29 % to approximately 2.77 % of the total share capital.

6. Are there any pending regulatory approvals? The filing indicates that all conditions under Regulation 10(1)(a)(ii) have been complied with, and no further approvals are required for the transaction to proceed.